These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 23751561)
1. Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris. Li J; Lin Y; Zhuang H; Hua ZC J Microbiol Biotechnol; 2013 Sep; 23(9):1197-205. PubMed ID: 23751561 [TBL] [Abstract][Full Text] [Related]
2. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy. Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863 [TBL] [Abstract][Full Text] [Related]
3. Expression, purification and biological characterization of human vasostatin120-180 in Pichia pastoris. Lin Y; Yang X; Lu M; Zhuang H; Hua ZC Protein Expr Purif; 2013 Dec; 92(2):141-7. PubMed ID: 24096091 [TBL] [Abstract][Full Text] [Related]
4. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. Zhu F; Jia S; Xing G; Gao L; Zhang L; He F DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166 [TBL] [Abstract][Full Text] [Related]
5. Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. Lin Y; Peng N; Li J; Zhuang H; Hua ZC Mol Cancer; 2013 Jun; 12():54. PubMed ID: 23758884 [TBL] [Abstract][Full Text] [Related]
6. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator. Zhao G; Yuan C; Bian C; Hou X; Shi X; Ye X; Huang Z; Huang M Protein Expr Purif; 2006 Sep; 49(1):71-7. PubMed ID: 16806969 [TBL] [Abstract][Full Text] [Related]
7. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121 [TBL] [Abstract][Full Text] [Related]
8. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777 [TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain. Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538 [TBL] [Abstract][Full Text] [Related]
10. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830 [TBL] [Abstract][Full Text] [Related]
11. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219 [TBL] [Abstract][Full Text] [Related]
12. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084 [TBL] [Abstract][Full Text] [Related]
13. Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris. Su M; Chang W; Zhang K; Cui M; Wu S; Xu T Oncol Rep; 2016 Feb; 35(2):1179-85. PubMed ID: 26718643 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Hu XW; Duan HF; Gao LH; Pan SY; Li YM; Xi Y; Zhao SR; Yin L; Li JF; Chen HP; Wu CT Cancer Biol Ther; 2008 May; 7(5):651-9. PubMed ID: 18245952 [TBL] [Abstract][Full Text] [Related]
15. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416 [TBL] [Abstract][Full Text] [Related]
16. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627 [TBL] [Abstract][Full Text] [Related]
17. Expression, purification and characterization of recombinant human angiogenin in Pichia pastoris. Xia WR; Fu WL; Cai L; Cai X; Wang YY; Zou MJ; Xu DG Biosci Biotechnol Biochem; 2012; 76(7):1384-8. PubMed ID: 22785483 [TBL] [Abstract][Full Text] [Related]
18. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells]. Zhu F; Xing G; He F Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013 [TBL] [Abstract][Full Text] [Related]
19. Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera. Errico Provenzano A; Posteri R; Giansanti F; Angelucci F; Flavell SU; Flavell DJ; Fabbrini MS; Porro D; Ippoliti R; Ceriotti A; Branduardi P; Vago R Microb Cell Fact; 2016 Nov; 15(1):194. PubMed ID: 27842546 [TBL] [Abstract][Full Text] [Related]
20. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Kargiotis O; Chetty C; Gogineni V; Gondi CS; Pulukuri SM; Kyritsis AP; Gujrati M; Klopfenstein JD; Dinh DH; Rao JS Int J Oncol; 2008 Nov; 33(5):937-47. PubMed ID: 18949356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]